ClinicalTrials.gg
CompletedNCT04125056Updated Oct 14, 2019

Study on Hydronidone Capsule BE

An interventional study of Hydronidone Capsule(Specification: 30 mg / grain) and Hydronidone Capsule(Specification: 15 mg / grain) in Healthy, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-14.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2019, registered Oct 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The purpose of this study was to compare the hydronidone capsules (specification: 30 mg/particle, test preparation) developed by Shanghai Ruixing Gene Technology corporation with Self reference preparation hydronidone capsule (specification: 15 mg/capsule) Differences in the extent and rate of absorption of healthy male subjects in Fasting state in China. Through the main pharmacokinetic parameters and relative bioavailability, whether the two are bioequivalent, and provide a basis for the registration of the test preparation

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Beijing Continent Pharmaceutical Co, Ltd. is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: Chinese healthy male subjects;
  2. Age: 18 to 65 years old, including 18 and 65 years old;
  3. Weight should not be less than 50 kg, (BMI) in the range of 19 to 26 (including the boundary value) ((BMI) = weight (kg) / height 2 (m2));
  4. The subject (or his or her partner) has no pregnancy plan during the trial period and 6 months after the end of the trial and voluntarily adopts effective physical and has no sperm donation or egg donation plan;
  5. Before the trial, you have a detailed understanding of the nature, significance, possible benefits, possible inconvenience and potential risks, and volunteered to participate in this clinical trial, to communicate well with the researchers, to comply with the requirements of the entire study, and to sign the written .

Exclusion criteria

Exclusion Criteria:

  1. (Questions) There are any diseases that may affect the safety of the test or the in vivo process of the drug, including but not limited to: liver, kidney, endocrine, cardiovascular, digestive, neurological, mental, respiratory, neoplastic, immune, skin, blood or Researchers of metabolic systems think that it is not suitable for the past medical history or existing medical history of the test [especially those with cardiovascular disease including cardiovascular disease risk, any gastrointestinal diseases affecting drug absorption (such as irritable bowel syndrome symptoms, bowel) History of disease or inflammatory bowel disease), active pathological hemorrhage (such as peptic ulcer), urticaria, epilepsy, asthma, etc. or other diseases that are not suitable for clinical trials;
  2. (Questions)allergies: such as those who are allergic to two or more drugs, food; lactose intolerance;
  3. (Questions)Any drug that inhibits or induces liver metabolism of the drug within 28 days prior to taking the study drug (common liver enzyme inducer: barbiturate (the most common phenobarbital), carbamazepine, ammonia Mitt, griseofulvin, methamphetamine, phenytoin, glutamine, rifampicin, dexamethasone; common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole Oxazole, chloramphenicol, isoniazid, sulfa drug); or any drug (including Chinese herbal medicine) and health care products used within 14 days before the first dose;
  4. (Questions) have special requirements for food, can not comply with a unified diet (such as intolerance to standard foods) or have difficulty swallowing;
  5. (Questions)Can not tolerate venipuncture and / or have a history of halo, fainting;
  6. (Questions)Overdose (over 8 cups a day, 1 cup = 250mL) tea, coffee or caffeinated beverages during the first three months of screening; or take any caffeine and jaundice from the screening to -1 day admission Food or beverage (such as coffee, tea, chocolate, etc.) and other special dieters that affect the absorption, distribution, metabolism, and excretion of drugs;
  7. (Questions)Drinking more than 14 standard units per week for the first 3 months of screening (1 standard unit containing 14 g of alcohol, such as 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine); or no alcohol during the test period Or study any alcohol-containing product within 24 hours prior to the first administration, and the result of the alcohol breath test is greater than 0.0 mg/100 mL;
  8. (Questions)Studying blood donation within 3 months prior to the first dose, including component blood or massive bleeding (greater than 450 mL), or planning to donate blood or blood components during the study period or within 3 months after the end of the study;
  9. (Questions)Acute disease occurs prior to the pre-study screening phase or prior to study medication;
  10. (Questions)Screened to a food or drink containing inducible or inhibited liver metabolic enzymes (such as grapefruit, mango, dragon fruit, grape juice, orange juice and other flavonoids or citrus glycosides) during admission;
  11. (Questions)Those who have undergone surgery within 3 months prior to screening, or who plan to undergo surgery during the study period, and those who have received surgery that affect drug absorption, distribution, metabolism, and excretion;
  12. (Questions)History of drug abuse, history of drug abuse; positive urine screening;
  13. (Questions)The number of cigarettes per day for the first 3 months of screening is greater than 5, or no tobacco products can be stopped during the trial; those who smoked or used any tobacco products during the screening period, and those with positive nicotine tests;
  14. Physical examination during screening, vital sign measurement, examination, laboratory examination (blood routine, urine routine, blood biochemistry, coagulation function), the investigator judged that the abnormality has clinical significance;
  15. surface antigen positive, or antibody positive, or syphilis antibody positive, or antibody positive;
  16. Those who have participated in any other clinical trials within 3 months prior to the trial;
  17. The investigator believes that there are any circumstances that may affect the subject's or follow the protocol, or participate in the trial that may affect the outcome of the trial or its own safety.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    test group

    Hydronidone capsules (Specification: 30 mg / capsule)

    Drug: Hydronidone Capsule(Specification: 30 mg / grain)

  • Placebo comparator
    Control group

    Hydronidone capsules (Specification: 15 mg / capsule)

    Drug: Hydronidone Capsule(Specification: 15 mg / grain)

Interventions

  • DrugHydronidone Capsule(Specification: 30 mg / grain)

    Drug page: Hydronidone

    Test group

  • DrugHydronidone Capsule(Specification: 15 mg / grain)

    Control group

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: up to 12 weeks

  2. AUC

    Time frame: up to 12 weeks

  3. Tmax

    Time frame: up to 12 weeks

Secondary outcomes

  1. λz

    Time frame: up to 12 weeks

07

Study locations

1 site
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jan 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2019
First posted
Oct 14, 2019
StartActual
Jan 16, 2019
Primary completionActual
Jan 23, 2019
CompletionActual
Mar 4, 2019
Last update
Oct 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04125056
Responsible party
Sponsor
First posted
Oct 14, 2019
Start date
Jan 16, 2019
Primary completion
Jan 23, 2019
Completion
Mar 4, 2019
Last update
Oct 14, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion